CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3
I'm PortAI, I can summarize articles.
China Resources Pharmaceutical Group Ltd. (HK:3320) reported a revenue increase to RMB 21.99 billion for the nine months ending September 30, 2025, up from RMB 19.74 billion, despite a net profit decline to RMB 2.90 billion from RMB 3.24 billion. The financial results indicate a decrease in cash and cash equivalents, alongside a rise in total assets and liabilities. Analysts rate the stock as a Hold with a price target of HK$5.50. The company operates in the pharmaceutical sector and has a market cap of HK$30.6 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments